$50M Share Buyback Signals Collegium's Confidence in ADHD Portfolio
Event summary
- Collegium Pharmaceutical launched a $50 million accelerated share repurchase (ASR) program with Jefferies LLC on August 13, 2026.
- The buyback is part of a $150 million share repurchase program authorized in July 2025, leaving $100 million remaining after this transaction.
- Initial delivery includes 1.56 million shares at $25.70 per share, with final settlement expected by Q4 2026.
- Collegium cited undervaluation and confidence in its ADHD portfolio as key motivations for the repurchase.
The big picture
Collegium's $50 million share buyback reflects confidence in its ADHD portfolio, which includes JORNAY PM and AZSTARYS. The move aligns with broader trends in biopharma where companies with strong cash flow are using repurchases to signal undervaluation. The transaction also highlights Collegium's disciplined capital allocation strategy amid a competitive ADHD market landscape.
What we're watching
- Valuation Disconnect
- Whether Collegium's share repurchase will close the perceived gap between its market valuation and long-term growth prospects.
- ADHD Portfolio Growth
- The pace at which Collegium can sustain revenue growth from its ADHD portfolio, particularly JORNAY PM and AZSTARYS.
- Debt Reduction Strategy
- How aggressively Collegium will reduce debt while balancing share repurchases and other capital allocation priorities.
Related topics